Eli Lilly’s experimental oral GLP-1 receptor agonist, orforglipron, has demonstrated comparable cardiovascular safety to insulin glargine while delivering superior blood-sugar reductions in a large clinical trial, potentially reshaping diabetes treatment options.
Orforglipron, an oral GLP-1 drug being developed by Eli Lilly, matched insulin glargine on cardiovascular safety in people with type 2 diabetes while producing stronger blood-sugar improvements, according to results presented at the European Association for the Study of Diabetes meeting in Milan and published in The Lancet. The trial, known as ACHIEVE-4, adds to a growing body of evidence that the once-daily pill could offer an easier-to-use alternative to injectable diabetes treatments. According to the research team, the drug also produced better reductions in HbA1c, the measure of long-term blood glucose control, and body weight.
The study enrolled 2,749 adults with type 2 diabetes, with a mean age of 63, and most had established cardiovascular disease; a substantial share also had chronic kidney disease. Participants were randomly assigned to receive either orforglipron once a day or insulin glargine injections. Over a median follow-up of about two years, major cardiovascular events occurred in 4.2% of patients taking orforglipron and 5.0% of those receiving insulin glargine, meeting the trial’s prespecified non-inferiority target. In practical terms, that means the oral drug was not shown to be worse than the insulin for heart safety within the margin the researchers had set in advance.
The findings are important because cardiovascular disease remains one of the leading causes of illness and death in type 2 diabetes, and safety is a key barrier when newer glucose-lowering medicines are assessed alongside established therapies. The trial’s sponsors said orforglipron also caused fewer clinically significant episodes of low blood sugar than insulin glargine, while previous phase 3 studies have shown the drug can reduce weight and improve glucose control compared with semaglutide, another GLP-1 treatment taken orally. Earlier research has also suggested the medicine has a consistent safety profile in Japanese patients and in obesity trials among people with type 2 diabetes.
For Eli Lilly, the latest data strengthen the case for orforglipron as a potentially more convenient option in a crowded diabetes market dominated by injectables. The company has already presented the drug as a key part of its broader GLP-1 strategy, and the new cardiovascular results may help determine how quickly clinicians view an oral alternative as comparable to established injectable therapies for patients who need long-term treatment.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
